Lung Cancer Clinical Trials in North Carolina

A listing of Lung Cancer clinical trials in North Carolina actively recruiting patient volunteers.

Home

All Clinical Trials

North Carolina

Lung Cancer

13 - 24 of 62

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

CMV Vaccine Trial For Young Women Ages 16-17

Recruiting

A Cytomegalovirus (CMV) Investigational Vaccine Clinical Trial for Healthy Women Age 16 to 17 years old. Compensation included.

Conditions:

Healthy Volunteers

Healthy

Learn More

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

Featured Trial

Paid Vaccine Study For Teens

Recruiting

Vaccine study that aims to protect teens ages 12–17 against Epstein-Barr virus (EBV) and infectious mononucleosis (mono).

Conditions:

Healthy

Healthy Volunteer Study

Learn More

Featured Trial

Adult Migraine Study

Recruiting

Migraine study for adults. You may be compensated up to $800 for your time and travel expenses.

Conditions:

Headache

Cluster Headache

Headache Disorders

Post-Traumatic Headache

Migraine

Menstrual Migraine

Classic Migraine

Migraine

With or Without Aura

Learn More

* Compensation for time may be available

A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer

NCT04702880

Recruiting

The purpose of this study is to demonstrate that treatment with BMS-986012 in combination with carboplatin, etoposide, and nivolumab will have acceptable safety and tolerability and will improve progression-free survival compared with carboplatin, etoposide, and nivolumab alone in newly diagnosed participants with extensive-stage small cell lung cancer (ES-SCLC).

Gender:

All

Ages:

18 years and above

Locations: Duke Cancer Institute, Durham, North Carolina +44 locations

University of Alabama at Birmingham, Birmingham, Alabama

Moffitt Cancer Center, Tampa, Florida

Local Institution, Lexington, Kentucky

John Theurer Cancer Center, Hackensack, New Jersey

Duke Cancer Institute, Durham, North Carolina

University of Cincinnati Medical Center, Cincinnati, Ohio

Local Institution, Cincinnati, Ohio

University Hospitals Cleveland Medical Center, Cleveland, Ohio

Tennessee Oncology Nashville, Nashville, Tennessee

Local Institution, Dallas, Texas

MultiCare Health System, Tacoma, Washington

Local Institution - 0003, Westmead, New South Wales

Local Institution - 0023, Greenslopes, Queensland

Local Institution, Ballarat, Victoria

Local Institution - 0001, Malvern, Victoria

Local Institution - 0004, Murdoch, Western Australia

Local Institution - 0051, Charleroi, Not set

Local Institution - 0034, Gent, Not set

Local Institution - 0050, Liège, Not set

Local Institution - 0012, Edmonton, Alberta

Local Institution - 0064, Brampton, Ontario

Local Institution - 0045, Heraklion, Irakleío

Local Institution - 0036, Athens, Not set

Local Institution - 0038, Athens, Not set

Casa di Cura Dott. Pederzoli, Peschiera del Garda, Not set

Local Institution - 0031, Pisa, Not set

Humanitas-U.O di Oncologia medica ed Ematologia, Rozzano, Not set

Local Institution - 0073, Sendai, Miyagi

Local Institution - 0070, Osaka-Sayama City, Osaka

Local Institution - 0069, Takatsuki, Osaka

Local Institution - 0077, Ina-machi, Saitama

Local Institution - 0039, Amsterdam, Not set

Local Institution - 0066, Arnhem, Not set

Local Institution - 0040, Groningen, Not set

Local Institution - 0079, Leiden, Not set

Local Institution, Nijmegen, Not set

Local Institution - 0049, Gdansk, Not set

Local Institution - 0048, Łódź, Not set

Local Institution - 0043, Bucharest, Not set

Local Institution - 0042, Cluj, Not set

Local Institution - 0041, Craiova, Not set

Local Institution - 0007, Barcelona, Not set

Local Institution - 0021, Madrid, Not set

Local Institution - 0005, Majadahonda, Not set

Local Institution - 0006, Málaga, Not set

Conditions: Extensive-stage Small Cell Lung Cancer

Learn More ›

A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

NCT04623775

Recruiting

The purpose of this study is to assess the safety profile of relatlimab plus nivolumab in combination with platinum doublet chemotherapy (PDCT) and to determine if nivolumab plus relatlimab in combination with PDCT improves overall response rate (ORR) when compared to nivolumab plus PDCT in participants with previously untreated Stage IV or recurrent non-small cell lung cancer (NSCLC).

Gender:

All

Ages:

18 years and above

Locations: Duke University Medical Center, Durham, North Carolina +163 locations

City of Hope, Duarte, California

University of California Irvine, Orange, California

UCLA Medicine-Hematology Oncology, Santa Monica, California

Yale School of Medicine - Smilow Cancer Hospital, New Haven, Connecticut

Christiana Care Health System, Newark, Delaware

Cancer Specialists of North Florida, Jacksonville, Florida

Local Institution - 0011, Port Saint Lucie, Florida

Local Institution - 0089, Athens, Georgia

Cancer Center of Kansas, Wichita, Kansas

Baptist Health Lexington, Lexington, Kentucky

Norton Cancer Institute, Louisville, Kentucky

New England Cancer Specialists - Kennebunk, Kennebunk, Maine

NECS, Scarborough, Maine

$Form.Name, Saint Louis, Missouri

Oncology Hematology West P.C. dba Nebraska Cancer Specialist, Omaha, Nebraska

Regional Cancer Care Associates, Howell, New Jersey

Montefiore Medical Center, Bronx, New York

Broome Oncology LLC, Johnson City, New York

NYU Perlmutter Cancer Center (Long Island), Mineola, New York

NYU Perlmutter Cancer Center, New York, New York

Memorial Sloan Kettering Cancer Center, New York, New York

Duke University Medical Center, Durham, North Carolina

University of Cincinnati Cancer Institute, Cincinnati, Ohio

The MetroHealth System, Cleveland, Ohio

Lancaster General Health, Lancaster, Pennsylvania

Allegheny General Hospital, Pittsburgh, Pennsylvania

Lifespan Cancer Institute, Providence, Rhode Island

St Francis Cancer Center, Greenville, South Carolina

SCCC Clinical Research Office, Dallas, Texas

Valley Cancer Associates PC, Harlingen, Texas

The University of Texas Health Science Center at Tyler DBA UT Health East Texas Hope Cancer Center, Tyler, Texas

Seattle Cancer Care Alliance, Seattle, Washington

Medical Oncology Associates, PS (dba Summit Cancer Centers), Spokane, Washington

West Virginia University, Morgantown, West Virginia

Local Institution - 0096, Mar Del Plata, Buenos Aires

Local Institution - 0037, Rio Cuarto, Cordoba

Local Institution - 0021, Buenos Aires, Distrito Federal

Local Institution - 0014, Caba, Distrito Federal

Local Institution - 0073, Capital, LA Rioja

Local Institution - 0039, Viedma, RIO Negro

Local Institution - 0029, Rosario, Santa Fe

Local Institution - 0060, Cordoba, Not set

Local Institution - 0038, Cordoba, Not set

Local Institution - 0055, Camperdown, New South Wales

Local Institution - 0086, Gosford, New South Wales

Local Institution - 0132, Tamworth, New South Wales

Local Institution - 0057, South Brisbane, Queensland

Local Institution - 0130, Ballarat, Victoria

Local Institution - 0138, Bendigo, Victoria

Local Institution - 0141, Box Hill, Victoria

Local Institution - 0109, Frankston, Victoria

Local Institution - 0033, Melbourne, Victoria

Local Institution - 0119, Murdoch, Western Australia

Local Institution - 0085, Nedlands, Western Australia

Local Institution - 0090, Graz, Not set

Local Institution - 0126, Vienna, Not set

Local Institution - 0066, Liege, Lige

Local Institution - 0125, Roeselare, West-Vlaanderen

Local Institution - 0127, Ghent, Not set

Local Institution - 0131, Ghent, Not set

Local Institution - 0063, Natal, RIO Grande DO Norte

Local Institution - 0122, Ijui, RIO Grande DO SUL

Local Institution - 0161, Ijui, Rio Grande Do Sul

Local Institution - 0116, Porto Alegre, RIO Grande DO SUL

Local Institution - 0112, Porto Alegre, RIO Grande DO SUL

Local Institution - 0107, Barretos, Sao Paulo

Local Institution - 0111, Santo Andre, SAO Paulo

Local Institution - 0072, Rio de Janeiro, Not set

Local Institution - 0163, Sao Paulo, Not set

Local Institution - 0120, Sao Paulo, Not set

Local Institution - 0118, Sao Paulo, Not set

Local Institution - 0098, Levis, Quebec

Local Institution - 0041, Santiago, Metropolitana

Local Institution - 0016, Santiago, Metropolitana

Local Institution - 0040, Santiago, Metropolitana

Local Institution - 0079, Santiago, Metropolitana

Local Institution - 0010, Bordeaux, Gironde

Local Institution - 0008, Rennes, Ille-Et-Vilaine

Local Institution - 0007, Dijon cedex, Not set

Local Institution - 0144, Le Mans, Not set

Local Institution - 0110, Paris, Not set

Local Institution - 0102, Paris, Not set

Local Institution - 0035, Paris, Not set

Local Institution - 0044, Saint Priest en Jarez, Not set

Local Institution - 0006, Saint-Mande, Not set

Local Institution - 0103, Berlin, Not set

Local Institution - 0045, Berlin, Not set

Local Institution - 0077, Dresden, Not set

Local Institution - 0065, Essen, Not set

Local Institution - 0062, Grosshansdorf, Not set

Local Institution - 0058, Homburg, Not set

Local Institution - 0108, Lowenstein, Not set

Local Institution - 0071, Marburg, Not set

Local Institution - 0093, Muenster, Not set

Local Institution - 0050, Paderborn, Not set

Local Institution - 0030, Ravensburg, Not set

Local Institution - 0133, Dublin, Not set

Local Institution - 0023, Dublin, Not set

Local Institution - 0003, Monselice, PD

Local Institution - 0106, Rome, RA

Local Institution - 0028, Candiolo, Not set

Local Institution - 0009, Catania, Not set

Local Institution - 0032, Genova Sampierdarena, Not set

Local Institution - 0076, Milano, Not set

Local Institution - 0059, Milano, Not set

Local Institution - 0164, Pesaro, Not set

Local Institution - 0078, Ravenna, Not set

Local Institution - 0019, Siena, Not set

Local Institution - 0070, Ciudad de Mexico, Distrito Federal

Local Institution - 0020, Toluca de Lerdo, Estado DE Mexico

Local Institution - 0115, Monterrey, Nuevo LEON

Local Institution - 0013, San Pedro Garza Garcia, Nuevo LEON

Local Institution - 0158, Arnhem, Not set

Local Institution - 0053, Harderwijk, Not set

Local Institution - 0094, Rotterdam, Not set

Local Institution - 0087, Christchurch, Canterbury

Local Institution - 0145, Gdynia, Not set

Local Institution - 0036, Lublin, Not set

Local Institution - 0031, Lublin, Not set

Local Institution - 0080, Olsztyn, Not set

Local Institution - 0088, Warszawa, Not set

Local Institution - 0099, Cluj Napoca, Cluj

Local Institution - 0017, Craiova, Dolj

Local Institution - 0052, Craiova, Jud. DOLJ

Local Institution - 0069, Timisoara, Timis

Local Institution - 0056, Baia Mare, Not set

Local Institution, Craiova, Not set

Arkhangelsk Clinical Oncological Dispensary, Arkhangelsk, Not set

Local Institution - 0064, Chelyabinsk, Not set

Local Institution - 0054, Moscow, Not set

Local Institution - 0004, Moscow, Not set

Local Institution - 0025, Nizghiy Novgorod, Not set

FSBI &quot,Research Institute of Influenza named after A.A. Smorodintsev &quot,of the MoH of the Rus, Saint Petersburg, Not set

LLC Eurocityclinic, Saint-Petersburg, Not set

Local Institution - 0042, Malaga, Andalucia

Local Institution - 0075, Sevilla, Andalucia

Local Institution - 0137, Badalona, Barcelona

Local Institution - 0061, Las Palmas de Gran Canaria, Las Palmas

Local Institution - 0051, A Coruna, Not set

Local Institution - 0154, Barcelona, Not set

Local Institution - 0048, Barcelona, Not set

Local Institution - 0024, Barcelona, Not set

Local Institution - 0074, Madrid, Not set

Local Institution - 0123, Madrid, Not set

Local Institution - 0043, Valencia, Not set

Local Institution - 0015, Basel, Not set

Local Institution - 0142, Lausanne, Not set

Local Institution - 0104, St. Gallen, Not set

Local Institution - 0046, Gokay Cad No:140, Kadikoy

Local Institution - 0022, Adana, Not set

Local Institution - 0068, Ankara, Not set

Local Institution - 0034, Antalya, Not set

Local Institution - 0114, Diyarbakir, Not set

Local Institution - 0018, Edirne, Not set

Local Institution - 0049, Erzurum, Not set

Local Institution - 0105, Istanbul, Not set

Local Institution - 0135, Middlesborough, Cleveland

Local Institution - 0136, Blackpool, Lancashire

Local Institution - 0095, Manchester, Lancashire

Local Institution - 0027, Guildford, Not set

Local Institution - 0100, Leeds, Not set

Local Institution - 0067, Leicester, Not set

Local Institution, London, Not set

Local Institution - 0140, Nottingham, Not set

Conditions: Recurrent Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer, Non-small Cell Lung Cancer

Learn More ›

Safety and Efficacy of Intravenous Cemiplimab Plus BNT116 Versus Cemiplimab Alone in Advanced Non-Small Cell Lung Cancer in Adult Participants With PD-L1 ≥ 50%

NCT05557591

Recruiting

The study is researching an investigational drug, called BNT116, in combination with cemiplimab. BNT116 and cemiplimab will each be called a "study drug", and together be called "study drugs" in this form. The study is focused on patients who have advanced non-small cell lung cancer (NSCLC). The aims of the study are to see how safe and tolerable BNT116 is in combination with cemiplimab and to see how effective BNT116 in combination with cemiplimab is compared to cemiplimab by itself at treatin... Read More

Gender:

All

Ages:

18 years and above

Locations: Oncology Specialists of Charlotte, Charlotte, North Carolina +3 locations

Conditions: Advanced Non-Small Cell Lung Cancer

Learn More ›

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

NCT05361395

Recruiting

This is a phase 1b study to assess the safety and tolerability of tarlatamab in combination with programmed death ligand (PD-L1) inhibition with and without chemotherapy.

Gender:

All

Ages:

18 years and above

Locations: The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina +41 locations

University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California

Christiana Care Health Services, Newark, Delaware

Henry Ford Health System, Detroit, Michigan

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

New York University Langone Medical Center, New York, New York

The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina

Avera Cancer Institute, Sioux Falls, South Dakota

Swedish Cancer Institute Medical Oncology, Seattle, Washington

West Virginia University Health Sciences Center, Morgantown, West Virginia

Chris OBrien Lifehouse, Camperdown, New South Wales

Universitair Ziekenhuis Antwerpen, Edegem, Not set

Algemeen Ziekenhuis Maria Middelares, Gent, Not set

Jessa Ziekenhuis - Campus Virga Jesse, Hasselt, Not set

AZ Delta Campus Rumbeke, Roeselare, Not set

CHU de Quebec Hopital de l Enfant Jesus, Quebec, Not set

Rigshospitalet, Kobenhavn, Not set

Centre Leon Berard, Lyon cedex 8, Not set

Centre Hospitalier Universitaire de Nantes, Hôpital Nord Laënnec, Saint Herblain, Not set

Gustave Roussy, Villejuif, Not set

Universitaetsklinikum Carl Gustav Carus, Dresden, Not set

Universitätsklinikum Essen, Essen, Not set

Universitätsklinikum Freiburg, Freiburg, Not set

Rambam Medical Center, Haifa, Not set

Hadassah Ein-Kerem Medical Center, Jerusalem, Not set

Rabin Medical Center, Petah Tikva, Not set

Azienda Ospedaliero Universitaria Mater Domini, Catanzaro, Not set

Fondazione IRCCS San Gerardo dei Tintori, Monza (MB), Not set

Istituti Fisioterapici Ospitalieri Regina Elena San Gallicano, Rome, Not set

National Cancer Center Hospital East, Kashiwa-shi, Chiba

The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Tokyo

Seoul National University Hospital, Seoul, Not set

Asan Medical Center, Seoul, Not set

Samsung Medical Center, Seoul, Not set

Universitair Medisch Centrum Groningen, Groningen, Not set

Institut Catala d Oncologia Badalona Hospital Universitari Germans Trias i Pujol, Badalona, Cataluña

Hospital Universitari Vall d Hebron, Barcelona, Cataluña

Hospital Universitario 12 de Octubre, Madrid, Not set

Universitaetsspital Basel, Basel, Not set

Inselspital Bern, Bern, Not set

National Cheng Kung University Hospital, Tainan, Not set

National Taiwan University Hospital, Taipei, Not set

Taipei Veterans General Hospital, Taipei, Not set

Conditions: Extensive Stage Small Cell Lung Cancer

Learn More ›

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

NCT04032704

Recruiting

This trial will study ladiratuzumab vedotin (LV) alone and with pembrolizumab to find out if it works to treat different types of solid tumors. It will also find out what side effects may occur. A side effect is anything the drug does besides treating cancer.

Gender:

All

Ages:

18 years and above

Locations: FirstHealth of the Carolinas, Pinehurst, North Carolina +65 locations

Ironwood Cancer & Research Centers - Chandler, Chandler, Arizona

Adventist Health White Memorial, Los Angeles, California

Saint Joseph Heritage Medical Group, Santa Rosa, California

Eastern CT Hematology and Oncology Associates, Norwich, Connecticut

GenesisCare USA, Jacksonville, Florida

AdventHealth Cancer Institute, Orlando, Florida

IACT Health, Columbus, Georgia

Northwestern University, Chicago, Illinois

Decatur Memorial Hospital, Decatur, Illinois

Fort Wayne Medical Oncology and Hematology, Fort Wayne, Indiana

University of Maryland, Baltimore, Maryland

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

HealthPartners Institute, Saint Louis Park, Minnesota

Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada

Valley Hospital, The / Luckow Pavilion, Paramus, New Jersey

San Juan Oncology Associates, Farmington, New Mexico

Weill Cornell Medicine, New York, New York

Stony Brook University Cancer Center, Stony Brook, New York

FirstHealth of the Carolinas, Pinehurst, North Carolina

Gabrail Cancer Center Research, LLC, Canton, Ohio

Providence Portland Medical Center, Portland, Oregon

Saint Francis Hospital / Bon Secours, Greenville, South Carolina

Erlanger Oncology and Hematology, Chattanooga, Tennessee

Tennessee Oncology-Nashville/Sarah Cannon Research Institute, Nashville, Tennessee

Joe Arrington Cancer Research and Treatment Center, Lubbock, Texas

UT Health East Texas Hope Cancer Center, Tyler, Texas

Carbone Cancer Center / University of Wisconsin, Madison, Wisconsin

Melanoma Institute Australia, Wollstonecraft, Other

Flinders Medical Centre, Bedford Park, Not set

Townsville Cancer Center, Douglas, Not set

Peninsula and South East Oncology, Frankston, Not set

Central Coast Local Health District (Gosford and Wyong Hospitals), Gosford, Not set

Royal Hobart Hospital, Hobart, Not set

Cabrini, Malvern, Not set

St Vincents Hospital Sydney, Sydney, Not set

Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi, Bologna, Not set

Azienda Ospedaliero Universitaria Careggi, Florence, Not set

ASL 3 Genovese Villa Scassi Hospital, Genova, Not set

San Luca Hospital, Lucca, Not set

Irccs Irst, Meldola, Not set

Istituto Europeo di Oncologia, Milano, Not set

Niguarda Ca' Granda Hospital, Milan, Not set

San Gerardo di Monza Hospital, Monza, Not set

Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Not set

Policlinico Universitario Agostino Gemelli, Rome, Not set

AOUS Policlininico Le Scotte, Siena, Not set

Dong-A University Hospital, Busan, Not set

Chonnam National University Hwasun Hospital, Hwasun, Not set

Seoul National University Bundang Hospital, Seongnam-si, Not set

Seoul National University Hospital, Seoul, Not set

Severance Hospital, Yonsei University Health System, Seoul, Not set

Samsung Medical Center, Seoul, Not set

Seoul National University Boramae Medical Center, Seoul, Not set

Korea University Guro Hospital, Seoul, Not set

St. Vincent's Hospital, The Catholic University of Korea, Suwon-si, Not set

Ajou University Hospital, Suwon-si, Not set

Taichung Veterans General Hospital, Taichung, Not set

National Cheng-Kung University Hospital, Tainan, Not set

National Taiwan University Hospital, Taipei, Not set

Taipei Medical University Hospital, Taipei, Not set

The Beatson West of Scotland Cancer Centre, Glasgow, Not set

The Royal Marsden Hospital, London, Not set

Sarah Cannon Research Institute UK, London, Not set

UCL Cancer Institute, London, Not set

The Christie NHS Foundation Trust, Manchester, Not set

The Royal Marsden Hospital (Surrey), Sutton, Not set

Conditions: Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma

Learn More ›

A Biomarker Screening Protocol to Support Preliminary Eligibility for Clinical Trials Evaluating Safety and Efficacy of Adoptive T-cell Therapies in Participants With Solid Tumors

NCT05891197

Recruiting

Biomarker Screening Protocol for Preliminary Eligibility Determination for Adoptive T-cell Therapy Trials:This is a decentralized, multi-site, US-based biomarker screening study to identify participants who have specific disease indications and tumor expression of target(s) of interest that may inform eligibility for active and future Lyell clinical trials. No investigational treatments will be administered in this non-interventional screening study. Only previously obtained archival tumor tissu... Read More

Gender:

All

Ages:

Between 18 years and 99 years

Locations: Accellacare of Rocky Mount -Dr. Bondy, Rocky Mount, North Carolina

Conditions: Triple Negative Breast Cancer, Nonsmall Cell Lung Cancer

Learn More ›

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative

NCT04929041

Recruiting

This phase II/III trial compares the addition of radiation therapy to the usual treatment (immunotherapy with or without chemotherapy [carboplatin, pemetrexed, paclitaxel, nab-paclitaxel]) versus (vs.) usual treatment alone in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic) whose tumor is also negative for a molecular marker called PD-L1. Stereotactic body radiation therapy (SBRT) is a type of radiation therapy that uses high energy x-rays to kill tumor cells and shrink tumors. This method uses special equipment to position a patient and precisely deliver radiation to tumors with fewer doses over a shorter period and may cause less damage to normal tissue than conventional radiation therapy. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Pemetrexed is in a class of medications called antifolate antineoplastic agents. It works by stopping cells from using folic acid to make DNA and may kill cancer cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Nab-paclitaxel is an albumin-stabilized nanoparticle formulation of paclitaxel which may have fewer side effects and work better than other forms of paclitaxel. The addition of radiation therapy to usual treatment may stop the cancer from growing and increase the life of patients with advanced non-small cell lung cancer who are PD-L1 negative. Read Less

Gender:

All

Ages:

18 years and above

Locations: Duke University Medical Center, Durham, North Carolina +105 locations

Mayo Clinic Hospital in Arizona, Phoenix, Arizona

Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California

City of Hope Comprehensive Cancer Center, Duarte, California

City of Hope Antelope Valley, Lancaster, California

Fremont - Rideout Cancer Center, Marysville, California

Providence Queen of The Valley, Napa, California

University of California Davis Comprehensive Cancer Center, Sacramento, California

City of Hope South Pasadena, South Pasadena, California

Gene Upshaw Memorial Tahoe Forest Cancer Center, Truckee, California

City of Hope Upland, Upland, California

UCHealth Memorial Hospital Central, Colorado Springs, Colorado

Memorial Hospital North, Colorado Springs, Colorado

Poudre Valley Hospital, Fort Collins, Colorado

Cancer Care and Hematology-Fort Collins, Fort Collins, Colorado

UCHealth Greeley Hospital, Greeley, Colorado

Medical Center of the Rockies, Loveland, Colorado

Beebe South Coastal Health Campus, Frankford, Delaware

Helen F Graham Cancer Center, Newark, Delaware

Medical Oncology Hematology Consultants PA, Newark, Delaware

Beebe Health Campus, Rehoboth Beach, Delaware

MedStar Washington Hospital Center, Washington, District of Columbia

Lewis Cancer and Research Pavilion at Saint Joseph's/Candler, Savannah, Georgia

Saint Luke's Cancer Institute - Boise, Boise, Idaho

Saint Luke's Cancer Institute - Fruitland, Fruitland, Idaho

Saint Luke's Cancer Institute - Meridian, Meridian, Idaho

Saint Luke's Cancer Institute - Nampa, Nampa, Idaho

Saint Luke's Cancer Institute - Twin Falls, Twin Falls, Idaho

Northwestern University, Chicago, Illinois

University of Illinois, Chicago, Illinois

University of Chicago Comprehensive Cancer Center, Chicago, Illinois

Carle at The Riverfront, Danville, Illinois

Decatur Memorial Hospital, Decatur, Illinois

Northwestern Medicine Cancer Center Kishwaukee, DeKalb, Illinois

Carle Physician Group-Effingham, Effingham, Illinois

Crossroads Cancer Center, Effingham, Illinois

Northwestern Medicine Cancer Center Delnor, Geneva, Illinois

Ingalls Memorial Hospital, Harvey, Illinois

Northwestern Medicine Lake Forest Hospital, Lake Forest, Illinois

Carle Physician Group-Mattoon/Charleston, Mattoon, Illinois

UC Comprehensive Cancer Center at Silver Cross, New Lenox, Illinois

University of Chicago Medicine-Orland Park, Orland Park, Illinois

Southern Illinois University School of Medicine, Springfield, Illinois

Springfield Clinic, Springfield, Illinois

Memorial Medical Center, Springfield, Illinois

Carle Cancer Center, Urbana, Illinois

Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois

Mary Greeley Medical Center, Ames, Iowa

McFarland Clinic PC - Ames, Ames, Iowa

Medical Oncology and Hematology Associates-West Des Moines, Clive, Iowa

Mercy Cancer Center-West Lakes, Clive, Iowa

Greater Regional Medical Center, Creston, Iowa

Mercy Medical Center - Des Moines, Des Moines, Iowa

Mission Cancer and Blood - Laurel, Des Moines, Iowa

Mercy Medical Center-West Lakes, West Des Moines, Iowa

Saint Joseph Hospital East, Lexington, Kentucky

MaineHealth Cancer Care Center of York County, Sanford, Maine

Maine Medical Center- Scarborough Campus, Scarborough, Maine

Maine Medical Partners - South Portland, South Portland, Maine

Saint Joseph Mercy Hospital, Ann Arbor, Michigan

Saint Joseph Mercy Brighton, Brighton, Michigan

Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton, Michigan

Saint Joseph Mercy Canton, Canton, Michigan

Trinity Health IHA Medical Group Hematology Oncology - Canton, Canton, Michigan

Saint Joseph Mercy Chelsea, Chelsea, Michigan

Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital, Chelsea, Michigan

Genesys Hurley Cancer Institute, Flint, Michigan

Hurley Medical Center, Flint, Michigan

Sparrow Hospital, Lansing, Michigan

Trinity Health Saint Mary Mercy Livonia Hospital, Livonia, Michigan

Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus, Ypsilanti, Michigan

Hennepin County Medical Center, Minneapolis, Minnesota

Regions Hospital, Saint Paul, Minnesota

Saint Francis Medical Center, Cape Girardeau, Missouri

Parkland Health Center - Farmington, Farmington, Missouri

Delbert Day Cancer Institute at PCRMC, Rolla, Missouri

Missouri Baptist Medical Center, Saint Louis, Missouri

Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri

Missouri Baptist Sullivan Hospital, Sullivan, Missouri

Missouri Baptist Outpatient Center-Sunset Hills, Sunset Hills, Missouri

Roswell Park Cancer Institute, Buffalo, New York

Mount Sinai Chelsea, New York, New York

Mount Sinai West, New York, New York

Mount Sinai Hospital, New York, New York

Upstate Cancer Center at Oneida, Oneida, New York

Upstate Cancer Center at Oswego, Oswego, New York

State University of New York Upstate Medical University, Syracuse, New York

SUNY Upstate Medical Center-Community Campus, Syracuse, New York

Duke University Medical Center, Durham, North Carolina

Duke Raleigh Hospital, Raleigh, North Carolina

Wake Forest University Health Sciences, Winston-Salem, North Carolina

Summa Health System - Akron Campus, Akron, Ohio

Cancer Centers of Southwest Oklahoma Research, Lawton, Oklahoma

University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma

Christiana Care Health System-Concord Health Center, Chadds Ford, Pennsylvania

Geisinger Medical Center, Danville, Pennsylvania

Penn State Milton S Hershey Medical Center, Hershey, Pennsylvania

Geisinger Medical Oncology-Lewisburg, Lewisburg, Pennsylvania

Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre, Pennsylvania

Medical University of South Carolina, Charleston, South Carolina

Gundersen Lutheran Medical Center, La Crosse, Wisconsin

Mayo Clinic Health System-Franciscan Healthcare, La Crosse, Wisconsin

Marshfield Medical Center-Marshfield, Marshfield, Wisconsin

Marshfield Clinic-Minocqua Center, Minocqua, Wisconsin

ProHealth D N Greenwald Center, Mukwonago, Wisconsin

ProHealth Oconomowoc Memorial Hospital, Oconomowoc, Wisconsin

UW Cancer Center at ProHealth Care, Waukesha, Wisconsin

Conditions: Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Advanced Lung Adenocarcinoma, Metastatic Lung Adenocarcinoma, Metastatic Lung Adenosquamous Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Adenosquamous Carcinoma

Learn More ›

Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients

NCT05375994

Recruiting

This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with adagrasib in patients with G12C Non-Small Cell Lung Cancer (NSCLC) who have been exposed to prior G12C inhibitor and experienced progressive disease.

Gender:

All

Ages:

18 years and above

Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina +5 locations

Conditions: Non Small Cell Lung Cancer, KRAS Activating Mutation, Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung, Malignant Neoplastic Disease

Learn More ›

Surgery Versus Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer

NCT05183932

Recruiting

The development of stereotactic body radiation therapy (SBRT) for the treatment of stage I non-small cell lung cancer (NSCLC) has inspired a close partnership between thoracic surgery and radiation oncology. In this study, patients with stage I NSCLC will be screened prior to treatment and will be consented after their treatment plan has been determined. Prospectively collected patient-reported outcomes (PROs) will be collected for 3 years, as will outcomes data.

Gender:

All

Ages:

18 years and above

Locations: Duke University, Durham, North Carolina +6 locations

Conditions: Non Small Cell Lung Cancer, Non-small Cell Lung Cancer

Learn More ›

Observational Trial to Predict Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

NCT05478538

Recruiting

The primary objective of this study is to determine the ex-vivo prognostic accuracy of the Cybrid live tumor diagnostic platform using in-vivo RECIST 1.1 as the reference method.

Gender:

All

Ages:

18 years and above

Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina +2 locations

Conditions: Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer, NSCLC, Metastatic NSCLC - Non-Small Cell Lung Cancer

Learn More ›

PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung

NCT05553834

Recruiting

PCSK9 mediates immune checkpoint blockade resistance by downregulating tumor cell surface MHC class 1 molecules. This study will evaluate if combining the anti-PCSK9 antibody alirocumab with the anti-PD-1 antibody cemiplimab can generate anti-tumor activity and clinical responses in patients with metastatic lung cancer who have progressed on first line immune checkpoint blockade therapy.

Gender:

All

Ages:

18 years and above

Locations: Duke University, Durham, North Carolina

Conditions: Non-small Cell Lung Cancer (NSCLC)

Learn More ›

MRD Assay Evaluates Recurrence and Response Via a Tumor Informed Assessment

NCT05219734

Recruiting

This study recruits patient with solid tumor types for sample collection and monitoring. Participants will provide blood and archival tissue samples in order to create a Personalized Cancer Monitoring (PCM) assay. This assay will be used to detect circulating tumor DNA (ctDNA) levels in the blood over time and hopefully contribute to improvements in residual disease detection methods for future patients. Results from this assay will be provided to participants and providers but providers are no... Read More

Gender:

All

Ages:

18 years and above

Locations: Onslow Radiation, Jacksonville, North Carolina +1 locations

Conditions: Cancer, Solid Tumor, Non Small Cell Lung Cancer, Colorectal Cancer, Bladder Cancer

Learn More ›

13 - 24 of 62

Browse by Lung Cancer Clinical Trials by City

Lung Cancer clinical trials in Charlotte

Lung Cancer clinical trials in Raleigh

Lung Cancer clinical trials in Greensboro

Lung Cancer clinical trials in Durham

Lung Cancer clinical trials in Fayetteville

Lung Cancer clinical trials in Cary

Lung Cancer clinical trials in Wilmington

Lung Cancer clinical trials in High Point

Lung Cancer clinical trials in Concord